{"id":"NCT02216071","sponsor":"Exela Pharma Sciences, LLC.","briefTitle":"Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa","officialTitle":"A Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study of the Comparative Efficacy and Safety of EXL CDOS in Subjects With Acute Otitis Externa","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-07-20","primaryCompletion":"2015-08-11","completion":"2015-08-11","firstPosted":"2014-08-13","resultsPosted":"2021-05-28","lastUpdate":"2021-05-28"},"enrollment":499,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Otitis Externa"],"interventions":[{"type":"DRUG","name":"Ciprodex速","otherNames":[]},{"type":"DRUG","name":"EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension","otherNames":["Ciprofloxacin 0.3% and Dexamethasone 0.1% Sterile Otic Suspension"]}],"arms":[{"label":"Ciprodex速, RLD","type":"ACTIVE_COMPARATOR"},{"label":"EXL CDOS","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to demonstrate the clinical therapeutic non-inferiority of EXL CDOS to commercially available Ciprofloxacin 0.3% and Dexamethasone 0.1% Sterile Otic Suspension (Ciprodex速, Alcon) in the treatment of acute otitis externa (AOE) when administered twice daily for 7 days.","primaryOutcome":{"measure":"Number of Participants With Clinical Cure of AOE","timeFrame":"7 days after the completion of therapy; at Day 15 (+/- 1 day)","effectByArm":[{"arm":"Ciprodex速, RLD","deltaMin":190,"sd":null},{"arm":"EXL CDOS","deltaMin":191,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":48,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":247},"commonTop":["Ear and labyrinth disorder","Infections and Infestations","Nercous system disorders","Injury, poisoning and procedural complications","Respiratory, thoracid and mediastinal disorders"]}}